STAT

FEBRUARY 7, 2024

The middle of the week is upon us. Meanwhile, do keep us in mind if you hear anything interesting. Rise and shine, everyone. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? Consider the alternatives, if you must. And what better way to make the time fly than to keep busy.

Diabetes 236

Diabetes 236

STAT

DECEMBER 4, 2023

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’

Vaccines 314

Vaccines 314

STAT

MAY 2, 2023

There was (and continues to be) a desperate hunger for definitive studies telling us how well specific measures would work, with specific publics, in specific settings, for specific strains of the novel and changing virus.

Vaccines 333

Vaccines 333

STAT

OCTOBER 6, 2023

If the Covid-19 pandemic has shown us one thing, it is how little we really know about how the human immune system works. Decoding and harnessing the power of the human immune system is one of the great frontiers of biomedicine.

Immunity 329

Immunity Immunization Vaccines 329

Pharmacy Times

AUGUST 18, 2022

A study suggests the paradigm of retail pharmacy is shifting, as customers are wanting more health and wellness-centered pharmacies as well as digital services.

49

49

STAT

NOVEMBER 16, 2023

And what pairs well with a biotech downturn? Our colleague Casey Ross joins us to tell the bombshell story of how the nation’s largest health insurer used a computer algorithm to deny patient care and boost its profitability. Who polices algorithms? How would you name the first approved CRISPR medicine?

187

187

STAT

DECEMBER 19, 2023

As for us, we are as busy as ever hunting and gathering items of interest. So join us as we hoist the ever-present cup of stimulation — our choice today is gingerbread — and attack the fast-growing to-do list. We trust you have your own busy agendas.

237

237

STAT

OCTOBER 19, 2022

” But when vaccines to prevent the disease were developed, those same leaders pushed low and middle-income countries to the back of the queue, outbidding poorer countries, as well as COVAX, a worldwide initiative developed to achieve equitable vaccine access, to secure vaccines for themselves.

Vaccines 292

Vaccines Pharmaceutical Companies Pharmaceutical Companies 292

STAT

JANUARY 19, 2024

My time was packed with the usual mix of requests from potential, current, and former clients as well as investors to discuss search projects, and of course the meeting requests from potential candidates. There was still plenty for us to do, and we’ve had some really great placements, but it was slower than the prior year.

220

220

STAT

SEPTEMBER 20, 2023

The middle of the week is upon us. Meanwhile, do keep us in mind if you hear anything interesting. … As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. Rise and shine, everyone. Have heart, though.

Compounding 192

Compounding Compounding Pharmacies Diabetes 192

STAT

FEBRUARY 1, 2023

The middle of the week is upon us and, since you made it this far, why not forge ahead? So please join us as we celebrate this notion with a cup or three of delicious stimulation. As always, please feel free to join us. The program is widely considered a success and has worked well for many drugs, but not all work out.

180

180

STAT

MARCH 12, 2024

As always, you are invited to join us. We hope your day goes well and, of course, do stay in touch. The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. Our choice today is an old stand-by: cinnamon hazelnut.

200

200

STAT

SEPTEMBER 8, 2022

Our colleague Matthew Herper joins us to discuss how Illumina, the biggest company in genomic sequencing, got into an $8 billion predicament. We also discuss a dramatic development for a new ALS treatment, the latest in cancer research, and a well-funded new player in biotech venture capital. Read the rest…

196

196

STAT

JANUARY 3, 2024

This calls for a cup of stimulation and we invite you to join us. Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups , STAT tells us. We are doing fine, thank you, especially given that this is the middle of the week. Perhaps you can relate.

214

214

pharmaphorum

JANUARY 19, 2024

The drug – a new dry powder intranasal formulation of the well-established migraine therapy dihydroergotamine mesylate (DHE) – was submitted for approval in the US last March as an easy-to-use, portable treatment option for acute migraine attacks, with or without aura, in adult patients.

105

105

STAT

MAY 24, 2023

We’ve all had the experience of a doctor or other health care worker staring at screen while asking us sensitive questions to fill out our electronic health records. But that frustrating experience is made even worse by a new trend in health care. Read the rest…

Hospitals 198

Hospitals 198

STAT

JANUARY 17, 2023

Yet disease — well, disease remains with us. ” Little was known about the then-mysterious cell therapy startup, except that it would pursue ideas “ that will seem unconnected to the current reality ” and, rumor had it, potentially raise an over $1 billion Series A. Today, Sana is a public company.

Diabetes 200

Diabetes 200

STAT

FEBRUARY 29, 2024

Cold winds and overcast skies will not deter us from celebrating another brand new day here on the Pharmalot campus, where the official mascots are hunting for creatures and a parade of driving machines is passing near by. As for us, we are engaged in the usual ritual — brewing cups of stimulation.

168

168

STAT

APRIL 4, 2023

This leaves us to focus on matters at hand, which start with brewing cups of stimulation — butter pecan, for those keeping track — and foraging for items of interest. Hope your day goes well, and do keep us in mind when something saucy occurs. Squirrels beware. Speaking of which, here is a new batch.

Diabetes 216

Diabetes 216

Pharmafile

FEBRUARY 27, 2024

Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. This will be the latest development in the company’s global operations as well as its most advanced facility at present. The facility is approximately 300,000 ft2 and is expected to employ 400 full-time staff.

69

69

STAT

AUGUST 3, 2023

As for us, we are dutifully concocting a few needed cups of stimulation as we dig in for another busy day. So hoist your own cup to a successful day and drop us a line when something interesting arises. So hoist your own cup to a successful day and drop us a line when something interesting arises. No doubt, you can relate.

Labelling 188

Labelling Diabetes 188

World Pharma News

NOVEMBER 10, 2023

Bayer and US-based Recursion Pharmaceuticals, Inc., The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform.

Compounding 107

Compounding 107

STAT

MARCH 14, 2023

As for us, we can see a steady flow of flurries outside our window, and we are keeping warm with another cup of stimulation. Please feel free to join us. We hope your days goes well and you conquer the world. Our choice today is blueberry cobbler.

Diabetes 197

Diabetes 197

STAT

MAY 3, 2024

Well, whatever you do, have a grand time. … Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate that is seen as a potential competitor to Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound , STAT tells us. The But be safe.

Documentation 200

Documentation Diabetes 200

STAT

DECEMBER 13, 2022

As for us, we are busy brewing another cup of stimulation. Please feel free to join us. With that said, we hope all goes well and that you conquer the world. Our choice today is the ever-so-sweet caramel apple. No sugar required.

Vaccines 209

Vaccines 209

STAT

AUGUST 1, 2023

Well, time to get cracking. So please join us for a daily ritual — a few cups of stimulation. And as always, please do keep us in mind if you hear something fascinating. A cool breeze and warm sun are enveloping the Pharmalot campus as we hunker down and sift through our ever-growing to-do list. A familiar exercise, yes?

Drug Pricing 222

Drug Pricing 222

assurecare

APRIL 17, 2024

Therefore, it's imperative for us to emphasize the importance of prioritizing employee well-being by cultivating a workplace environment that encourages a healthy equilibrium between personal and professional life. Employee Well-being: Employee well-being is the cornerstone of a productive and engaged workforce.

Communication 52

Communication 52

Express Pharma

JANUARY 31, 2024

Developed by Pfizer, abrocitinib has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) in India and is approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.

100

100

Pharmafile

FEBRUARY 7, 2023

This follows an approval from the EMA’s Committee for Medicinal Products for Human Use in December. The drug is already approved in the EU for the treatment of type 2 diabetes as well as chronic kidney disease. It has also received regulatory approvals in Britain, Japan and Turkey, as well as the US and now the EU.

Diabetes 105

Diabetes Communication 105

European Pharmaceutical Review

MARCH 20, 2024

At present, the Genentech Vacaville facility in the US has a total bioreactor capacity of around 330,000 litres. More about the deal Upon closing of the deal, the US Vacaville site will be integrated into Lonza’s Biologics division.

88

88

Digital Pharmacist

MARCH 19, 2024

Their focus on holistic health and lifestyle-based solutions have contributed to an emphasis on mental health and to recent upticks in organic and wellness trends. Approach to Holistic Health and Wellness Gen Zers favor getting and staying healthy over traditional healthcare visits.

104

104

Express Pharma

JANUARY 3, 2024

Brands include MenoFit and MenoGlow probiotics, Happy Fiber and Well Rested dietary supplements, Athena’s Shield menopause support supplement, and Goodness Glow and Keep Glowing Gorgeous supplements for healthy aging support.

101

101

Pharmaceutical Technology

APRIL 18, 2023

IntelGenx Corp announced that the US Food and Drug Administration (FDA) has approved the company’s Rizafilm VersaFilm new drug application (NDA) for the treatment of acute migraine. Rizafilm, the US market name for Rizaport outside of the US, is administered via an oral soluble film.

98

98

Express Pharma

MARCH 31, 2023

Granules India recently inaugurated and launched its packaging facility through its Granules Consumer Health (GCH) step-down subsidiary which is located in Manassas, Virginia, US. The facility recently received US FDA approval with zero 483 observations. million into its US packaging facility.

Packaging 74

Packaging 74

Express Pharma

MAY 2, 2024

Dr Bhaskar Krishna, MD and CEO at Maiva Pharma said, “This fundraise will be used to add more vial, lyophilization, and suspension capacity and introduce new manufacturing capabilities such as prefilled syringes, cartridges and bags.” We are delighted to partner with Maiva in its vision to become a global leader in sterile injectables.”

Dosage 76

Dosage 76

Pharmaceutical Business Review

MARCH 5, 2024

This new eyedrop will enter a market valued at $1.3bn, driven by nearly seven million ocular surgeries performed per year in the US. In August last year, Formosa signed a licencing agreement granting sole US rights for marketing APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) to Eyenovia.

59

59

Pharmafile

JANUARY 27, 2023

The FDA is calling on the US Congress to work with them on a new regulatory pathway for cannabidiol (CBD). CBD is the non-psychoactive ingredient from the cannabis plant generally considered to have wellness properties. According to the FDA, there have been some safety concerns around CBD, especially with its long-term use.

Communication 88

Communication 88